Interventions
ADVERSE EVENTS
All patients received pamiparib 40 mg orally twice daily plus tislelizumab 200 mg IV Q3W (Supplementary Fig. If required to manage adverse events (AEs), pamiparib dose reduction to 20 mg was permitted, and dosing could also be withheld for up to 28 days consecutively. No dose reduction was permitted for tislelizumab, but dose delays of less than 12 weeks were permitted. Whether an AE was possibly related to either pamiparib or tislelizumab alone, or both, was assessed by the investigator, and the study drug(s) considered to be responsible were modified accordingly.